Skip to content
BBIO·Nasdaq·US

BridgeBio

BridgeBio is a biotechnology company focused on developing and commercializing medicines for genetic diseases and selected cancers with clear genetic drivers. It has a commercial product franchise and a pipeline of clinical and preclinical drug programs, including gene-therapy candidates and partnered development assets.

Thematic Position

BBIO

Relationship Groups

Partners4
Licensing2
Competitors14

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

9 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

government funding rightsmarch-in rightsmanufacturing requirement
U.S. government march-in rights over federally funded patent technology
SEC 10-QMay 7, 2026

The full regulatory passage is part of the Pro plan.

13 more · Regulatory and geopolitical insights are part of the Pro plan.